News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Bispecific antibody delivers positive results in relapsed, refractory multiple myeloma
08 Jun 2024
byJairia Dela Cruz
A large percentage of patients with relapsed/refractory multiple myeloma (RRMM) respond to the bispecific antibody linvoseltamab, with deep and durable responses seen even in the high-risk subgroups, according to data from the phase I/II LINKER-MM1 trial.
08 Jun 2024

ART discontinuation tied to toxicity, disease progression in mCRPC patients
07 Jun 2024
Several patients with metastatic castration-resistant prostate cancer (mCRPC) discontinue the use of androgen receptor‒targeted therapies (ARTs) because of disease progression, while a few stopped ARTs due to treatment toxicity, according to a study.
07 Jun 2024






